company background image
NTLA logo

Intellia Therapeutics NasdaqGM:NTLA Stock Report

Last Price

US$24.27

Market Cap

US$2.3b

7D

-4.1%

1Y

-38.2%

Updated

15 Apr, 2024

Data

Company Financials +

Intellia Therapeutics, Inc.

NasdaqGM:NTLA Stock Report

Market Cap: US$2.3b

NTLA Stock Overview

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics.

NTLA fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Intellia Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Intellia Therapeutics
Historical stock prices
Current Share PriceUS$24.27
52 Week HighUS$47.48
52 Week LowUS$22.67
Beta1.8
1 Month Change-14.24%
3 Month Change-9.30%
1 Year Change-38.17%
3 Year Change-63.95%
5 Year Change49.45%
Change since IPO9.82%

Recent News & Updates

Intellia Therapeutics Is On The Move

Feb 29

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Feb 24
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Recent updates

Intellia Therapeutics Is On The Move

Feb 29

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Feb 24
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Intellia's Bet On In-Vivo Breakthroughs: A Perspective On CRISPR's Next Frontier

Feb 09

Is Intellia Therapeutics (NASDAQ:NTLA) In A Good Position To Deliver On Growth Plans?

Feb 07
Is Intellia Therapeutics (NASDAQ:NTLA) In A Good Position To Deliver On Growth Plans?

Is There An Opportunity With Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) 25% Undervaluation?

Jan 01
Is There An Opportunity With Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) 25% Undervaluation?

Intellia Therapeutics (NASDAQ:NTLA) Is In A Good Position To Deliver On Growth Plans

Oct 20
Intellia Therapeutics (NASDAQ:NTLA) Is In A Good Position To Deliver On Growth Plans

Intellia Therapeutics: Top Speculative Trade In The Biotech Space

Oct 05

Intellia wins FDA orphan drug designation for genome editing therapy for severe swelling

Sep 01

Is Intellia Therapeutics (NASDAQ:NTLA) Weighed On By Its Debt Load?

Aug 06
Is Intellia Therapeutics (NASDAQ:NTLA) Weighed On By Its Debt Load?

Intellia Therapeutics down 12% following bottom line Q2 earnings miss

Aug 04

Intellia: Slim Hopes Of Near-Term Commercial Revenue Makes Me Bearish

Jul 28

Intellia Therapeutics: Several Catalysts Expected For H2 2022

May 12

Intellia: One Patent Ruling Turns The Industry Upside Down

Mar 09

Intellia Therapeutics: A Lot Of News Can Bring The Stock Up

Feb 25

Need To Know: The Consensus Just Cut Its Intellia Therapeutics, Inc. (NASDAQ:NTLA) Estimates For 2022

Feb 09
Need To Know: The Consensus Just Cut Its Intellia Therapeutics, Inc. (NASDAQ:NTLA) Estimates For 2022

Intellia: Best All-Around Gene Editing Company

Jan 27

We Think Intellia Therapeutics (NASDAQ:NTLA) Can Afford To Drive Business Growth

Dec 31
We Think Intellia Therapeutics (NASDAQ:NTLA) Can Afford To Drive Business Growth

Intellia Has Potential As Gene Therapy Play With Second Product Being Tested In Humans

Dec 15

Intellia Stock: Setting Up For Success

Nov 29

Intellia: A Step Closer To A Life-Changing Cure

Nov 21

Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) Intrinsic Value Is Potentially 79% Above Its Share Price

Oct 11
Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) Intrinsic Value Is Potentially 79% Above Its Share Price

Intellia's Data Has Underlined Huge Potential Of Gene Therapeutics And There Will Be More Soon

Aug 31

Here's Why We're Not At All Concerned With Intellia Therapeutics' (NASDAQ:NTLA) Cash Burn Situation

Aug 01
Here's Why We're Not At All Concerned With Intellia Therapeutics' (NASDAQ:NTLA) Cash Burn Situation

Estimating The Intrinsic Value Of Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Jul 05
Estimating The Intrinsic Value Of Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Intellia Makes History. Can It Deliver A Cure?

Jun 28

Intellia Therapeutics Q1 2021 Earnings Preview

May 05

Intellia Expands Its In Vivo Advantage

May 02

Companies Like Intellia Therapeutics (NASDAQ:NTLA) Can Afford To Invest In Growth

Apr 16
Companies Like Intellia Therapeutics (NASDAQ:NTLA) Can Afford To Invest In Growth

Broker Revenue Forecasts For Intellia Therapeutics, Inc. (NASDAQ:NTLA) Are Surging Higher

Mar 12
Broker Revenue Forecasts For Intellia Therapeutics, Inc. (NASDAQ:NTLA) Are Surging Higher

Shareholder Returns

NTLAUS BiotechsUS Market
7D-4.1%-2.8%-1.7%
1Y-38.2%-0.2%22.4%

Return vs Industry: NTLA underperformed the US Biotechs industry which returned -0.2% over the past year.

Return vs Market: NTLA underperformed the US Market which returned 22.4% over the past year.

Price Volatility

Is NTLA's price volatile compared to industry and market?
NTLA volatility
NTLA Average Weekly Movement8.8%
Biotechs Industry Average Movement11.6%
Market Average Movement6.1%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.0%

Stable Share Price: NTLA's share price has been volatile over the past 3 months.

Volatility Over Time: NTLA's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2014526John Leonardwww.intelliatx.com

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company’s in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases.

Intellia Therapeutics, Inc. Fundamentals Summary

How do Intellia Therapeutics's earnings and revenue compare to its market cap?
NTLA fundamental statistics
Market capUS$2.33b
Earnings (TTM)-US$481.19m
Revenue (TTM)US$36.28m

64.3x

P/S Ratio

-4.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NTLA income statement (TTM)
RevenueUS$36.28m
Cost of RevenueUS$435.07m
Gross Profit-US$398.79m
Other ExpensesUS$82.40m
Earnings-US$481.19m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-5.01
Gross Margin-1,099.36%
Net Profit Margin-1,326.51%
Debt/Equity Ratio0%

How did NTLA perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.